Ceritinib-related interstitial lung disease improving after treatment cessation without recurrence under either crizotinib or brigatinib: a case report.
Fiche publication
Date publication
mars 2019
Journal
Annals of translational medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MENNECIER Bertrand, Dr BENDER Laura
Tous les auteurs :
Bender L, Meyer G, Quoix E, Mennecier B
Lien Pubmed
Résumé
Anaplastic lymphoma kinase inhibitors (ALKi) like ceritinib are considered standard for front-line treatment of non-small cell lung cancers (NSCLC) harboring a translocation of the anaplastic lymphoma kinase (ALK) gene. We report herein a case of interstitial lung disease (ILD) that developed following a 7-month ceritinib treatment without recurrence under either crizotinib or brigatinib, two others ALKi.
Mots clés
Anaplastic lymphoma kinase rearrangement (ALK rearrangement), ceritinib, diffuse interstitial pneumonitis, non-small cell lung cancer (NSCLC)
Référence
Ann Transl Med. 2019 Mar;7(5):106